Invention Publication
- Patent Title: LOW POWER STIMULATED EMISSIONS NMR USING RABI TRANSITIONS FOR THE DETECTION OF MOLECULES [BIOLOGICS WITH 15N, 14N, 1H, AND 13C] THROUGH THE USE OF MATCHED FILTER LIBRARIES OF RESONANCE CHARACTERISTICS ASSOCIATED WITH THE MOLECULES
-
Application No.: US17917011Application Date: 2021-03-23
-
Publication No.: US20230341488A1Publication Date: 2023-10-26
- Inventor: John T. Apostolos , William Mouyos , James D. Logan , Walter Chase
- Applicant: AMI RESEARCH & DEVELOPMENT, LLC
- Applicant Address: US NH Merrimack
- Assignee: AMI RESEARCH & DEVELOPMENT, LLC
- Current Assignee: AMI RESEARCH & DEVELOPMENT, LLC
- Current Assignee Address: US NH Merrimack
- International Application: PCT/US21/23636 2021.03.23
- Date entered country: 2022-10-05
- Main IPC: G01R33/465
- IPC: G01R33/465
![LOW POWER STIMULATED EMISSIONS NMR USING RABI TRANSITIONS FOR THE DETECTION OF MOLECULES [BIOLOGICS WITH 15N, 14N, 1H, AND 13C] THROUGH THE USE OF MATCHED FILTER LIBRARIES OF RESONANCE CHARACTERISTICS ASSOCIATED WITH THE MOLECULES](/abs-image/US/2023/10/26/US20230341488A1/abs.jpg.150x150.jpg)
Abstract:
A high-speed, portal-based system that can rapidly identify the presence of viruses such as COVID-19 and its antibodies in vivo. The system uses a low-power, stimulated emissions Nuclear Magnetic Resonance (NMR) effect and associated signal processing to detect the presence of organics characteristic of the virus (such as 15N, 14N, 1H, and/or 13C). The walkthrough portal enables non-invasive, real-time screening at a low cost. Detection can be reliably made in vivo when the virus or antibody is present in the saliva, chest, lungs, or other organs at total counts as low as 108 copies per ml.
Information query